Prognostic value of pre‑treatment peripheral blood markers in pancreatic ductal adenocarcinoma and their association with S100A4 expression in tumor tissue

Li,Hua; Tian,Xiangdong; Xu,Yong; Pan,Yi; Huang,Yubei; Zhou,Dejun; Song,Zhenguo

doi:10.3892/ol.2019.10809

Prognostic value of pre‑treatment peripheral blood markers in pancreatic ductal adenocarcinoma and their association with S100A4 expression in tumor tissue

Authors:
- Hua Li
- Xiangdong Tian
- Yong Xu
- Yi Pan
- Yubei Huang
- Dejun Zhou
- Zhenguo Song
View Affiliations

Affiliations: Department of Endoscopic Diagnosis and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Department of Epidemiological Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Department of Anesthesiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Clinical Research Center for Cancer, Tianjin 300060, P.R. China
Published online on: September 5, 2019 https://doi.org/10.3892/ol.2019.10809
Pages: 4523-4534
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aims of the present study were to clarify the prognostic value of peripheral blood variables in patients with pancreatic ductal adenocarcinoma (PDAC), including the neutrophil‑to‑lymphocyte ratio (NLR), platelet‑to‑lymphocyte ratio (PLR) and lymphocyte‑to‑monocyte ratio (LMR), and to determine the association between these variables and S100 calcium‑binding protein A4 (S100A4) expression in tumor tissue, which is another prognostic factor for PDAC. Patients with PDAC were recruited at the Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) between December 2008 and December 2014. A retrospective analysis was performed based on the recorded pre‑treatment hematological parameters and clinical data. The prognostic value of NLR, PLR and LMR was examined. The association between these variables and S100A4 tissue expression was analyzed. Descriptive statistics and χ2 analyses were used in the present study. The median overall survival (OS) time of patients with PDAC was 9 months (range, 1‑32 months). Univariate analysis revealed that NLR, LMR, carbohydrate antigen 19‑9, surgery, chemotherapy, stage at diagnosis, tumor grade and age significantly affected OS. Although PLR exhibited no significant effects on OS, NLR and LMR were independent prognostic factors according to the multivariate analysis. Unpaired Student's t‑test revealed differences between S100A4 expression and NLR, PLR and LMR. The results of the present study indicated that low NLR and high LMR were associated with a favorable prognosis in patients with PDAC. As a simply obtained and widely available index at diagnosis, NLR and LMR may become a novel predictive and classifying marker for PDAC in the clinical setting.

View Figures

View References

1	Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J and Olive D: Pancreatic ductal adenocarcinoma: A strong imbalance of good and bad immunological cops in the tumor microenvironment. Front Immunol. 9:10442018. View Article : Google Scholar : PubMed/NCBI
2	Zheng L, Xue J, Jaffee EM and Habtezion A: Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology. 144:1230–1240. 2013. View Article : Google Scholar : PubMed/NCBI
3	Shi C, Merchant N, Newsome G, Goldenberg DM and Gold DV: Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. Archives Pathol Lab Med. 138:220–228. 2014. View Article : Google Scholar
4	Hernandez JM, Cowgill SM, Al-Saadi S, Collins A, Ross SB, Cooper J, Villadolid D, Zervos E and Rosemurgy A: CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg. 13:349–353. 2009. View Article : Google Scholar : PubMed/NCBI
5	Winter JM, Yeo CJ and Brody JR: Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 107:15–22. 2013. View Article : Google Scholar : PubMed/NCBI
6	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
7	Marengo E and Robotti E: Biomarkers for pancreatic cancer: Recent achievements in proteomics and genomics through classical and multivariate statistical methods. World J Gastroenterol. 20:13325–13342. 2014. View Article : Google Scholar : PubMed/NCBI
8	Roxburgh CS and McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 6:149–163. 2010. View Article : Google Scholar : PubMed/NCBI
9	Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, Go H, Kim JE, Kim CW and Huh J: The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in hodgkin's lymphoma: Correlation with tumor-associated macrophages. Oncologist. 17:871–880. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kaynar M, Yildirim ME, Badem H, Cavis M, Tekinarslan E, Istanbulluoglu MO, Karatas OF and Cimentepe E: Bladder cancer invasion predictability based on preoperative neutrophil-lymphocyte ratio. Tumour Biol. 35:6601–6605. 2014. View Article : Google Scholar : PubMed/NCBI
11	Tanoglu A and Karagoz E: Neutrophil and platelet-to-lymphocyte ratio: New predictors of dropout and recurrence after liver transplantation for hepatocellular cancer? Transplant Int. 27:e80–e81. 2014. View Article : Google Scholar
12	McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 12:223–226. 2009. View Article : Google Scholar : PubMed/NCBI
13	Martin HL, Ohara K, Kiberu A, Van Hagen T, Davidson A and Khattak MA: Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer. Intern Med J. 44:676–682. 2014. View Article : Google Scholar : PubMed/NCBI
14	Aliustaoglu M, Bilici A, Seker M, Dane F, Gocun M, Konya V, Ustaalioglu BB and Gumus M: The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology. 57:640–645. 2010.PubMed/NCBI
15	Sierzega M, Lenart M, Rutkowska M, Surman M, Mytar B, Matyja A, Siedlar M and Kulig J: Preoperative neutrophil-lymphocyte and lymphocyte-monocyte ratios reflect immune cell population rearrangement in resectable pancreatic cancer. Ann Surg Oncol. 24:808–815. 2017. View Article : Google Scholar : PubMed/NCBI
16	Garrett SC, Varney KM, Weber DJ and Bresnick AR: S100A4, a mediator of metastasis. J Biol Chem. 281:677–680. 2006. View Article : Google Scholar : PubMed/NCBI
17	Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N and de Groot JF: Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 20:187–198. 2014. View Article : Google Scholar : PubMed/NCBI
18	Hansen MT, Forst B, Cremers N, Quagliata L, Ambartsumian N, Grum-Schwensen B, Klingelhofer J, Abdul-Al A, Herrmann P, Osterland M, et al: A link between inflammation and metastasis: Serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4. Oncogene. 34:424–435. 2015. View Article : Google Scholar : PubMed/NCBI
19	Dahlmann M, Kobelt D, Walther W, Mudduluru G and Stein U: S100A4 in cancer metastasis: Wnt signaling-driven interventions for metastasis restriction. Cancers (Basel). 8:E592016. View Article : Google Scholar : PubMed/NCBI
20	Grum-Schwensen B, Klingelhofer J, Grigorian M, Almholt K, Nielsen BS, Lukanidin E and Ambartsumian N: Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. Cancer Res. 70:936–947. 2010. View Article : Google Scholar : PubMed/NCBI
21	Yao R, Davidson DD, Lopez-Beltran A, MacLennan GT, Montironi R and Cheng L: The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol. 22:1025–1032. 2007.PubMed/NCBI
22	Ai KX, Lu LY, Huang XY, Chen W and Zhang HZ: Prognostic significance of S100A4 and vascular endothelial growth factor expression in pancreatic cancer. World J Gastroenterol. 14:1931–1935. 2008. View Article : Google Scholar : PubMed/NCBI
23	Kamarajah SK, Burns WR, Frankel TL, Cho CS and Nathan H: Validation of the american joint commission on cancer (AJCC) 8th edition staging system for patients with pancreatic adenocarcinoma: A surveillance, epidemiology and end results (SEER) analysis. Ann Surg Oncol. 24:2023–2030. 2017. View Article : Google Scholar : PubMed/NCBI
24	Tian X, Zhou D, Chen L, Tian Y, Zhong B, Cao Y, Dong Q, Zhou M, Yan J, Wang Y, et al: Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway. Cell Death Dis. 9:542018. View Article : Google Scholar : PubMed/NCBI
25	Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR and Berry DP: Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 35:868–872. 2011. View Article : Google Scholar : PubMed/NCBI
26	Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F and Ghaneh P: Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 197:466–472. 2009. View Article : Google Scholar : PubMed/NCBI
27	Kakkat S, Rajan R, Sindhu RS, Natesh B and Raviram S: Comparison of platelet-lymphocyte ratio and CA 19-9 in differentiating benign from malignant head masses in patients with chronic pancreatitis. Indian J Gastroenterol. 36:263–267. 2017. View Article : Google Scholar : PubMed/NCBI
28	Asari S, Matsumoto I, Toyama H, Shinzeki M, Goto T, Ishida J, Ajiki T, Fukumoto T and Ku Y: Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: The neutrophil-lymphocyte and platelet-lymphocyte ratios. Surg Today. 46:583–592. 2016. View Article : Google Scholar : PubMed/NCBI
29	Jia W, Gao XJ, Zhang ZD, Yang ZX and Zhang G: S100A4 silencing suppresses proliferation, angiogenesis and invasion of thyroid cancer cells through downregulation of MMP-9 and VEGF. Eur Rev Med Pharmacol Sci. 17:1495–1508. 2013.PubMed/NCBI
30	Tsukamoto N, Egawa S, Akada M, Abe K, Saiki Y, Kaneko N, Yokoyama S, Shima K, Yamamura A, Motoi F, et al: The expression of S100A4 in human pancreatic cancer is associated with invasion. Pancreas. 42:1027–1033. 2013. View Article : Google Scholar : PubMed/NCBI
31	Mahon PC, Baril P, Bhakta V, Chelala C, Caulee K, Harada T and Lemoine NR: S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res. 67:6786–6795. 2007. View Article : Google Scholar : PubMed/NCBI
32	Lee SH, Kim H, Hwang JH, Shin E, Lee HS, Hwang DW, Cho JY, Yoon YS, Han HS and Cha BH: CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival. Pancreas. 43:380–388. 2014. View Article : Google Scholar : PubMed/NCBI
33	Arumugam T, Ramachandran V, Gomez SB, Schmidt AM and Logsdon CD: S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 18:4356–4364. 2012. View Article : Google Scholar : PubMed/NCBI
34	Langley RR and Fidler IJ: The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 128:2527–2535. 2011. View Article : Google Scholar : PubMed/NCBI
35	Knudsen ES, Vail P, Balaji U, Ngo H, Botros IW, Makarov V, Riaz N, Balachandran V, Leach S, Thompson DM, et al: Stratification of pancreatic ductal adenocarcinoma: Combinatorial genetic, stromal, and immunological markers. Clin Cancer Res. 23:4429–4440. 2017. View Article : Google Scholar : PubMed/NCBI
36	Raphael BJ, Hruban RH, Aguirre AJ, Moffitt RA, Yeh JJ, Stewart C, Robertson AG, Cherniack AD, Gupta M, Getz G, et al: Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 14:185–203. 2017. View Article : Google Scholar